Latest Articles and Analysis

RFK Jr's dismantling of CDC scientific leadership replaces expertise with anti-vaccine ideology and predetermined policy conclusions.

Trump administration's revocation of competition executive order accelerates healthcare consolidation and threatens patient access.

Most Favored Nation pricing threatens to import restrictive QALY-based frameworks that discriminate against expensive treatments.

HRSA clarifies 340B eligibility for STI clinics while manufacturers challenge Ryan White program participation.

HRSA's 340B pilot program replicates existing successful models rather than addressing structural program exploitation.

Proposed PEPFAR defunding would eliminate the world's most successful global HIV program and damage international health capacity.

Q3 2025 Watch: critical analysis including Cure Hepatitis C Act proposing subscription treatment models.

Expiration of enhanced ACA subsidies threatens to increase premiums 75% and reduce marketplace enrollment by millions.

340B program expansion drains billions from state Medicaid budgets while failing to deliver promised drug cost savings.

Impending HIV care crisis results from Medicaid work requirements, federal funding cuts, and healthcare system fragmentation.

Ukraine's integrated addiction care model outperforms U.S. fragmented approach despite war devastation and resource constraints.

Pharmaceutical industry engagement of patient advocates requires transparency about funding, conflicts of interest, and advocacy independence.

RFK Jr's Administration for a Healthy America proposes to dismantle infectious disease capacity while emphasizing unproven chronic disease theories.

Healthcare policy equality forms the foundation for LGBTQ+ liberation and health equity in prevention and treatment access.

Caregiving infrastructure supports health equity and healthcare outcomes, requiring policy investment in caregiving infrastructure.

CMS draft guidance on 340B claims modifiers creates ambiguity and enforcement gaps threatening program integrity and beneficiary access.

RFK Jr's budget testimony reveals plans to restructure HHS agencies and shift funding away from infectious disease prevention.

Antibiotic-resistant bacteria threaten basic medical procedures while drug development incentives prove inadequate for innovation.

Pharmacy benefit managers extract billions while adding no value, increasing costs without improving patient access or health outcomes.

Historical redlining policies correlate with current geographic disparities in HIV treatment access and care quality.